TY - JOUR T1 - 抗核抗体和亚临床间质性肺疾病在社区居住成人：梅萨研究JF - 欧洲呼吸杂志JO - EUR呼吸杂志DO - 10.1183 / 13993003.02262-2019 SP - 1902262 AU - 伯恩斯坦，绮J. AU - 奥斯汀, John H.M. AU - Kawut, Steven M. AU - Raghu, Ganesh AU - Hoffman, Eric A. AU - Newell, John D. AU - Watts, Jubal R. AU - Hrudaya Nath, P. AU - Sonavane, Sushilkumar K. AU - Graham Barr, R. AU - Lederer, David J. Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/01/03/13993003.02262-2019.abstract N2 - The presence of a systemic autoimmune rheumatic disease (ARD) is a well-known risk factor for interstitial lung disease (ILD). For example, 33% of adults with rheumatoid arthritis (RA) have subclinical ILD [1]. Higher serum levels of IgM rheumatoid factor (RF), IgA RF, and anti-cyclic citrullinated peptide antibody 2 are associated with subclinical ILD in community-dwelling adults [2]. It is unknown whether this relationship between autoimmunity and subclinical ILD is limited to RA-related autoantibodies, or extends more broadly to other epitopes. High attenuation areas (HAA) and interstitial lung abnormalities (ILA) are validated quantitative and qualitative subclinical ILD phenotypes, respectively.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Bernstein reports grants from NIH/NIAMS, grants and personal fees from Boehringer Ingelheim, grants from Pfizer, outside the submitted work.Conflict of interest: Dr. Austin has nothing to disclose.Conflict of interest: Dr. Kawut has served in an advisory capacity (for grant review and other purposes) for United Therapeutics, Akros Pharmaceuticals, Glaxo SmithKline, and Complexa, Inc. without financial support or in-kind benefits.Conflict of interest: Dr. Raghu reports grants and personal fees from Boehringer Ingleheim, outside the submitted work.Conflict of interest: Eric A. Hoffman, PhD is a founder and share holder of VIDA Diagnostics, a company commercializing lung image analysis software developed, in part, at the University of Iowa.Conflict of interest: Dr. Newell reports grants from NIH, during the conduct of the study; personal fees from VIDA, grants from NIH, grants from Siemens Healthineers, outside the submitted work; In addition, Dr. Newell has a patent with VIDA issued, and a patent with University of Iowa issued.Conflict of interest: Dr. Watts reports personal fees from Genentech, personal fees from Boehringer Ingelheim, personal fees from France Foundation, outside the submitted work.Conflict of interest: Dr. Nath has nothing to disclose.Conflict of interest: Dr. Sonavane reports grants from NIH, during the conduct of the study.Conflict of interest: Dr. Barr reports grants from NIH, during the conduct of the study; grants from NIH, grants from COPD Foundation, outside the submitted work.Conflict of interest: Dr. Lederer is a full time employee of Regeneron Pharmaceuticals. The work in this article was performed solely while Dr. Lederer was an employee of Columbia University and does not represent work by Regeneron Pharmaceuticals, Inc. Dr. Lederer reports personal fees from Roche, Sanofi Genzyme, Philips Respironics, Fibrogen, Global Blood Therapeutics, Boehringer-Ingelheim, Veracyte, and Galapagos unrelated to the current work; institutional grant support from Fibrogen, Global Blood Therapeutics, and Boehringer-Ingelhim. He has performed unpaid consulting work for Galecto, Pliant therapeutics, and Bristol Myers Squibb. Columbia University has received fees from the Pulmonary Fibrosis Foundation for Dr. Lederer's consulting services. ER -